key: cord-0784031-khgqe1ql authors: Janeba, Zlatko title: Development of Small‐Molecule Antivirals for Ebola date: 2015-07-14 journal: Med Res Rev DOI: 10.1002/med.21355 sha: b7e61ccceea752b46749b9a600caf9882de7502f doc_id: 784031 cord_uid: khgqe1ql Ebola hemorrhagic fever is a deadly disease caused by infection with one of the Ebola virus species. Although a significant progress has recently been made in understanding of Ebola virus biology and pathogenesis, development of effective anti‐Ebola treatments has not been very productive, compared to other areas of antiviral research (e.g., HIV and HCV infections). No approved vaccine or medicine is available for Ebola but several are currently under development. This review summarises attempts in identification, evaluation, and development of small‐molecule candidates for treatment of Ebola viral disease, including the most promising experimental drugs brincidofovir (CMX001), BCX4430, and favipiravir (T‐705). Ebolavirus, Marburgvirus (MARV), and Cuevavirus are the only genera of the Filoviridae family of enveloped viruses with nonsegmented negative-sense RNA genoms. 1 They are causative agents of severe viral hemorrhagic fevers (VHFs) and are classified as biosafety level-4 (BSL-4) pathogens and Category A agents (in terms of bioterrorism). 2 The taxonomy of the Filoviridae family has kept changing over time and several virus names and abbreviations have been created. Currently, five ebola species (earlier they were considered strains or subtypes of one species) are recognized, namely Zaire ebolavirus (EBOV), Sudan ebolavirus (SUDV), Taï Forest ebolavirus (TAFV), Reston ebolavirus (RESTV), and Bundibugyo ebolavirus (BDBV). 1, 3 Especially, EBOV and SUDV are responsible for serious outbreaks of Ebola hemorrhagic fever (EHF), or Ebola virus disease (EVD), among humans and nonhuman primates in the regions of sub-Saharan Africa. EBOV is the most virulent ebola virus with fatality rate ranging from 50 to 90%. EVD was first identified in 1976 in Sudan (now South Sudan) 4 and Zaire (now the Democratic Republic of the Congo) 5 and 24 outbreaks were reported by the World Health Organization (WHO) since then through 2013. 6 The transmissions from animals to humans are believed Figure 1 . Chemical structures of nucleoside analogues with various modes of action: ribavirin (not active against EBOV); 3-deazaaristeromycin, 3-deazaneplanocin A and "D-like" 1 ,6 -isoneplanocin A (SAH hydrolase inhibitors); dUY11 (fusion inhibitor); BCX4430, CDV, and CMX001 (viral transcription inhibitors); compounds 1-3 (unknown mechanism of action). This group of compounds is represented by structurally modified nucleosides and nucleotides with various modes of antiviral action. Acyclic nucleoside phosphonates, and compounds that can be metabolized to nucleotide analogues in cells are also included here. Among nucleoside analogues, ribavirin (Virazole, Fig. 1 ), a broad-spectrum antiviral drug, has received a lot of attention. 28 Ribavirin has been reported to be active against some hemorrhagic fever viruses (e.g., Rift Valley fever virus and Crimean-Congo hemorrhagic fever virus), but it had no in vitro or in vivo effects on Ebola and Marburg viruses. 29 Later, number of structural adenosine analogues, for example, 3-deazaaristeromycin (C-c 3 Ado, Fig. 1 ) and 3deazaneplanocin A (c 3 -Npc A, Fig. 1 ), were discovered to inhibit replication of EBOV in vitro by blocking S-adenosyl-L-homocystein (SAH) hydrolase. [30] [31] [32] SAH hydrolase is a key enzyme in methylation reactions depending on Sadenosylmethionine (SAM) as the methyl donor and it has a key role in the methylation of 5 -end guanine of viral messenger RNA (regulation of capping process). Since the discovery of SAH hydrolase as a valuable pharmacological target for antiviral chemotherapy, 33 a large variety of adenosine (Ado) analogues as potential SAH hydrolase inhibitors have been reported. [34] [35] [36] Such inhibitors block the cleavage of S-adenosyl-L-homocystein (SAH) into homocysteine (Hcy) and adenosine, which itself can be further metabolized into AMP, adenine, and inosine. As a consequence of the SAH hydrolase inhibition, SAH accumulates in the cell and leads to an inhibition of the SAM-dependent methylation processes, including those that are required for the maturation (i.e., 5 -capping) of viral mRNAs. As a consequence, maturation of viral mRNAs is suppressed, and so is the production of progeny virus particles. 3-Deazaaristeromycin (C-c 3 Ado, Fig. 1 ) was the first compound that demonstrated to cure mice from otherwise lethal EBOV infection. 31 Bray et al. 32 showed that 3-deazaneplanocin A (Fig. 1) , as a single inoculation of 1 mg/kg, given on the first or second day after virus infection, also afforded a significant protection of mice against a lethal infection with EBOV without causing acute toxicity. In later study, 37 it was discovered that the protective effect of 3-deazaneplanocin A might result from massively increased production of interferon-α in Ebola-infected, but not uninfected mice. SAH hydrolase inhibitors have received only limited clinical evaluation and should be further tested for their potential antifilovirus properties as they exert a broad-spectrum antiviral activity and represent an attractive antiviral strategy. 38 Ye and Schneller 39 have reported 1 ,6 -isoneplanocin A enantiomers (e.g., "D-like" 1 ,6isoneplanocin A, Fig. 1 ) as compounds potent against a variety of important viruses, including EBOV with submicromolar EC 50 values (e.g., EC 50 = 0.38 for the "D-like" enantiomer, Fig. 1 ). The author also speculated that SAH hydrolase inhibition is not the only site of action of the "L-like" enantiomer and more studies are needed to fully understand the antiviral potential of L-like carbocyclic nucleosides. 39 Rigid amphipathic fusion inhibitors (RAFIs), 40 for example, compound dUY11 ( Fig. 1) , are uridine nucleoside analogues bearing a bulky hydrophobic group in the C-5 position. RAFIs represent another group of synthetic compounds that inhibit infectivity of several unrelated enveloped viruses, including HCV and HSV-1 and HSV-2 at submicromolar range and with no cytotoxic or cytostatic effects (selectivity index > 3000). 40 It was shown that RAFIs inhibit virion fusion as a result of their shape and amphipathicity. RAFIs should be further evaluated against other emerging viruses, such as EBOV and MARV. Another promising EBOV therapy represents compound BCX4430 (Fig. 1) , 41 which has been reported in 2014 as a novel broad-spectrum antiviral agent. It is an adenine analogue of the so-called Immucillin H, 42 a powerful transition-state analogue 43 inhibitor of purine nucleoside phosphorylase, which has a potential for treatment of human T-cell leukemia and lymphoma. BCX4430 exhibits broad-spectrum activity against numerous viruses, including filo-, bunya-, arena-, paramyxo-, corona-, and flaviviruses. BCX4430 was shown to inhibit infection of distinct filoviruses in human cells and postexposure intramuscular administration of BCX4430 protected rodents both against EBOV and MARV viral disease. 41 It, moreover, completely protected cynomolgus macaques from MARV infection when administered as late as 48 hr following infection. BCX4430 appeared to inhibit viral RNA polymerase function, acting probably as a non-obligate RNA chain terminator. 41 BCX4430 also effectively treated yellow fever virus (YFV) infection in a hamster model, even when treatment was initiated at the peak of viral replication. 44 The first-in-man Phase I study to evaluate the safety, tolerability, and pharmacokinetic properties of BCX4430 administered via intramuscular injection in healthy volunteers was announced by BioCryst Pharmaceuticals (Durham, NC, USA) in the middle of December 2014. 45 Brincidofovir (CMX001, BCV, HDP-CDV, Fig. 1 ) is an oral nucleotide analogue with broad-spectrum in vitro and in vivo antiviral activity against dsDNA viruses that effect humans, 46 including adenoviruses, 47, 48 poxviruses, 49 and herpesviruses. 50 CMX001 is a hexadecyloxypropyl prodrug of cidofovir ( Fig. 1) , 51 acyclic nucleoside phosphonate 52 approved by FAD for treatment of cytomegalovirus (CMV) infections. CMX001, being developed by Chimerix (Durham, NC, USA), has several key advantages compared to the parent compound: improved oral bioavailability, rapid transport across cell membranes leading to higher intracellular concentrations of the active species, greater potency, and elimination of nephrotoxicity. 53, 54 Brincidofovir has actually received Fast Track designation from the FDA for treatment of CMV, adenovirus, and smallpox infections. Quite surprisingly, investigational antiviral brincidofovir, which was considered by antiviral experts to be specific for treatment of DNA viral diseases, has been reported 55 to show in vitro activity against EBOV and, thus, to have potential use in patients with EVD. While additional assessments of CMX001 in animal model studies are being conducted through the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH), Chimerix announced in October 2014 that Emergency Investigational New Drug Applications (EIND) for brincidofovir were authorized by the US Food and Drug Administration (FDA) for EVD patients. 55 CMX001 probably interferes with certain enzyme(s) of nucleos(t)ide metabolism, but its exact mechanism of EBOV inhibition remains to be clarified. A class of imidazole nucleoside and nucleotide analogues, bearing either nitrile or ester groups at imidazole 4-and 5-positions (compounds of general structure 1 and 2, Fig. 1 ), has been reported to inhibit replication of Lassa virus, severe acute respiratory syndrome (SARS) coronavirus, and EBOV in vitro, employing real-time PCR. 56 Acyclic nucleotide analogue 3 ( Fig. 1 ), for example, showed IC 50 of 12 μg/mL and CC 50 of 75 μg/mL, suggesting that the reported activity may be linked to cytotoxicity. The IC 50 values of all the compounds against EBOV ranged from 10 to 52 μg/mL and the mechanism of action of these analogues remained speculative. 56 Favipiravir (T-705, Fig. 2 ), 57, 58 or 6-fluoro-3-hydroxypyrazine-2-carboxamide, is a broadspectrum antiviral agent active against many RNA viruses, as alpha-, arena-, bunya-, flavi-, noro-, orthomyxo-, and picornaviruses. It was discovered and developed by Toyama Chemical Co. (Toyama, Japan) as anti-influenza virus agent, 59, 60 and is approved in Japan as an influenza treatment under the brand name Avigan. Favipiravir is currently undergoing Phase III clinical trials in the United States. The in vivo efficacy of T-705 was recently confirmed in a mouse models for EBOV, when postexposure initiation of T-705 administration completely prevented the lethal consequences. 61, 62 In vitro, T-705 is efficiently converted by cellular enzymes to its ribofuranosyl 5-triphosphate (T-705 RTP, Fig. 2 ), the active species that was suggested to selectively inhibit influenza virus RNA-dependent RNA polymerase. 60 T-705 RTP is recognized by influenza A virus polymerase as an efficient substrate for incorporation to the RNA both as a guanosine and an adenosine analogue and its two consecutive incorporations were shown to prevent further primer extension. 63 Baranovich et al. 64 have reported lethal mutagenesis to be the key antiviral mechanism of T-705, that also explains its broad-spectrum antiviral activity. Favipiravir has been given to several Ebola patients and with its unique mechanism of action currently represents a very promising candidate for EVD treatment. r JANEBA This section includes structurally diverse compounds that are reported to inhibit the cell entry of filoviruses. Several of the agents discussed are repurposed FDA-approved drugs. Number of compounds of distinct structural features has been reported as potential entry inhibitors. EBOV entry requires functioning cholesterol transporter protein Niemann-Pick C1 (NPC1). 65 It was shown that cells defective NPC1 function, which binds to the viral GP, are resistant to infection by EBOV and MARV. Small-molecule inhibitors, derived from benzylpiperazine adamantane diamides (e.g., compounds 3.0 and 3.47, Fig. 3 ), 66 have been described that interfere with GP binding to NPC1. Since this process is essential for EBOV infection, it seems to represent a good target for potential antiviral therapy. Wolf et al. 67 have reported the discovery of promising broad-spectrum antiviral agent, LJ001 (Fig. 3) , active against an impressive number of enveloped viruses. It was effective against influenza A, filo-, pox-arena-, bunya-, paramyxo-, flaviviruses, and HIV, but had no effect on the infection of nonenveloped viruses. LJ001 intercalates into viral membranes preventing viruscell fusion, but the host cells can overcome the toxic effects of LJ001 due to their repair by cellular lipid biosynthesis. The rhodanine derivative LJ001 was suggested to inhibit viral entry at a step after virus binding and before virus-cell fusion, but the molecular target and molecular mechanism remained elusive. Later, Vigant et al. 68 identified the unsaturated fatty acid chains of viral membrane phospholipids as the major target of LJ001 antiviral activity. In the membrane bilayer, LJ001 generates singlet oxygen ( 1 O 2 ) and subsequent lipid oxidation results in changes to the biophysical properties of the viral membrane that disrupts the virus ability to undergo viruscell fusion. Furthermore, elucidation of the mode of action and subsequent structure-activity relationship (SAR) optimization of LJ001 led to a new class of oxazolidine-2,4-dithiones, for example, compound JL103 (Fig. 3) , 68 as membrane-targeted photosensitizers with increased potencies, 1 O 2 quantum yields, and red-shifted absorption spectra. A series of benzodiazepine compounds, represented by derivative 4 (Fig. 3) , has been reported as potential entry inhibitors for filoviruses. 69 Compound 4 was validated as an inhibitor of EBOV and MARV in cell-based assays, with 50% inhibitory concentrations (IC 50 s) of 10 and 12 μM, respectively. It was hypothesized that it binds to the hydrophobic pocket of the EBOV GP1-GP2 interface and as a consequence inhibits EBOV infection of cells. Pyridinyl imidazole inhibitors of p38 MAP kinase, for example, compound SB202190 (Fig. 3) , were found to impair viral entry and reduce cytokine induction by EBOV. 70 SB202190 reduced viral replication in macrophage-like human THP-1 cells with an IC 50 = 4.73 μM and primary human monocyte derived dendritic cells (MDDCs) with an IC 50 = 2.67 μM. Kinase, as well as phosphatase inhibitors may represent new leads and a unique strategy for antifilovirus therapeutic development and such compounds with reported anti-EBOV activity have recently been reviewed in depth. 21 Yermolina et al. 71 have reported a novel group of selective inhibitors of filoviral entry that selectively inhibit the EBOV and MARV GP mediated infection of human cells. Extensive SAR study led to an identification of lead compound 5 (Fig. 3) as a selective inhibitor of filoviral entry with an IC 50 of 30 μM. 71 Also several natural products that are able to impair microfilament function, including latrunculin A (Fig. 3) and cytochalasins, were shown to be potent inhibitors of EBOV virus GP mediated entry and fusion. 72 A novel high-throughput screening (HTS) assay of some 5000 small molecules led to an identification of novel broad-spectrum compounds able to block cathepsin L (CatL) cleavage of viral GPs derived from SARS-CoV and EBOV, Hendra, and Nipah viruses that are required for their entry into the host cell. 73 Parent compound 5705213 (Fig. 3 ) and its derivative 7402683 (Fig. 3) showed IC 50 s of 15 and 10 μM against EBOV-GP, respectively, and are not cytotoxic. Fullerene sugar balls represent a new class of biologically active compounds. 74 Watersoluble glycofullerenes were found to efficiently inhibit a DC-SIGN-dependent (DC-SIGN is a C-type lectin) cell infection by virus-like particles. 75 Several mannosylated fullerene sugar balls showed remarkable IC 50 s of 2 μM against EBOV and thus can be considered as a very promising tool to interfere with the EBOV entry. Drug repurposing (or drug repositioning) is potential application of known compounds to new indications. Therefore, a systematic screening of FDA-approved drugs could rapidly become available for a new indication in an emergency, including EBOV infections. [76] [77] [78] Chlorpromazine (trademarketed as Thorazine, Largactil, and Megaphen, Fig. 3) , 79 a known psychotropic drug approved by the FDA, was reported as potential inhibitor of EBOV entry, possibly through inhibition of clathrin-mediated endocytosis. 80 FDA-approved selective estrogen receptor modulators (SERMs), including clomifene (trademarked as Androxal, Clomid, and Omifin, Fig. 3 ) and toremifene (brand name Fareston) were identified as potent inhibitors of EBOV infection from an in vitro screening of readily available approved drugs. 77, 81, 82 The authors suggested that mode of the action of SERMs did not involve classical pathways associated with the estrogen receptor, but instead, interfere with a late step in viral entry. 81 Antiarrhytmic agents amiodarone (a multi-ion channel inhibitor, Fig. 3 ) and dronedarone are other examples of FDA-approved drugs that could be repurposed. 83 Amiodarone 84 was found to inhibit filovirus entry at concentrations (1.5-2.5 μg/mL) that are routinely reached in human serum during antiarrhythmic therapy. 83 The above examples show that drug repurposing may be a viable approach for identification of potent anti-EBOV therapeutics. Functional Genetics, Inc. (Gaithersburg, MD, USA) has reported a series of polyaromatic compounds active against distinct viruses. A small-molecule inhibitor of filovirus infection, designated as FGI-103 (Fig. 4) , 85 was identified via HTS of compound library from National Cancer Institute (NCI). FGI-103 exhibited antiviral activity against wild-type EBOV and SUDV, as well as multiple strains of MARV. 85 Although the mechanism of its action is unknown, it was shown in the murine model of EBOV infection that FGI-103 reduces viremia and viral burden in organ tissues and that it could be applicable for both prophylactic and therapeutic treatments. FGI-106 (Fig. 4) 86 is a diazachrysene (DAAC) based analogue that was discovered in a cell-based HTS as a potent and broad-spectrum inhibitor of lethal VHF pathogens, including EBOV, Rift Valley, and Dengue Fever viruses. FGI-106 protected mice from otherwise lethal EBOV infection both in prophylactic and therapeutic settings. FGI-106 also revealed potential inhibitory activity against other viral pathogens including HIV and HCV, 86 but the precise mode of action remains unclear. 22 The broad-spectrum nature of the antiviral activity of DAAC-based analogues may suggest targeting of a conserved host pathway. 86 Conventional antivirals are designed to target virally encoded proteins/enzymes and mechanisms. The disadvantage of the conventional antivirals is often their toxicity to the host and development of the resistant viral strains rendering them relatively quickly ineffective. To prevent the resistance problem, combination therapies using a cocktail of drugs with various modes of actions were successfully introduced and approved. Host-directed therapeutics represents another important approach to combat established, as well as emerging viral diseases. 87 Such approach is based on targeting host to deny the viral pathogen the ability to cause disease. Structural modification studies of the promising DAAC-based inhibitors were performed, 88, 89 and compound 6 ( Fig. 4) was identified as highly efficacious EBOV and MARV inhibitor with IC 50 values of 0.70 and 2.76 μM, respectively, with little or no associated cellular toxicity. 89 Recently, a broad-spectrum small-molecule inhibitor of EBOV, FGI-104 (structure originally not given), 90 has been reported that might target host protein TSG101 that plays an essential role in the viral life cycle. The interaction of filovirus matrix protein VP40, the key VP that drives the budding process, 91 with TSG101 facilitates the viral budding. 92 In addition, FGI-104 demonstrated inhibition of multiple emerging viruses (e.g., EBOV, Cowpox) and blood-borne pathogens (e.g., HBV, HCV, HIV). In the patent, 93 chaotically, FGI-104 is a name used for the whole family of compounds and R19 (Fig. 4) is mentioned as the preferred compound listed there. Retinoid thiosemicarbazone derivative, retinazone (RTZ, Fig. 5 ), 94 was described as a broad-spectrum antiviral agent active against HIV, HCV, VZV, and CMV. RTZ was found to be a potent suppressor of HCV RNA replicon replication. 94 Later, RTZ has also been reported to be potent and efficacious inhibitor of EBOV with an IC 50 value of 1.1 μM, 95 but since the SI 50 was only 3.4, the activity may be linked to cytotoxicity. Iminosugar 1-deoxynojirimycin (DNJ) and its derivatives (as glucose mimics) can serve as glucosidase inhibitors and were shown to exhibit antiviral effects against a number of enveloped viruses. DNJ derivative CM-10-18 (Fig. 5 ) was shown to exhibit in vitro and in vivo inhibitory activity against endoplasmic reticulum (ER) α-glucosidases I and II, 96, 97 and demonstrated in vivo efficacy against lethal Dengue virus infection in mice. 98 Further extensive SAR studies of CM-10-18 derivatives lead to an identification of novel iminosugars, for example, compound IHVR17028 (Fig. 5) , that significantly reduced the mortality of MARV and EBOV infections in mice. 99 A significant survival rate was, for example, observed for 25 mg/kg of IHVR17028 in a murine protection-of-death model of EBOV infection, when the treatment was initiated 4 hr post virus challenge. The multifunctional VP35 is another attractive therapeutic target as it plays a critical role in Ebola viral replication, and knowledge of high-resolution structures of the VP35 C-terminal domain (termed VP35 IID) 100 provides an opportunity for further structure-based antiviral research. 101 Using in silico and NMR-based screening methods, Brown et al. 102 identified several compounds, for example, representative compound GA017 (Fig. 5) , capable of binding of VP35 IID with high affinity and specificity. Some of the compounds were also shown to inhibit a replication-competent EBOV in a cell-based assay. 102 Recent HTS of a subset of FDA-approved drugs has reported that also antimalarials amodiaquine and chloroquine were active in vitro and in vivo against EBOV in single digit micromolar range, 76, 77 but the mechanism of action was unclear. Later it was shown 103 that these compounds docked favorably in VP35 suggesting they may be targeting this VP. Furthermore, chloroquine was shown to block EBOV virus like particle entry at an IC50 ß15 μM with selectivity index SI > 32. 77 Small-molecule screening for EBOV inhibitors leads to identification of NSC 62914 (Fig. 5) . 104 The compound acts as a scavenger of reactive oxygen species (ROS) and it upregulates oxidative stress induced genes. ROS contribute to the pathogenesis of a wide array of Budding of a broad range of RNA viruses is facilitated by subversion of host proteins (e.g., Nedd4) by viral PPxY late budding domains expressed within the matrix proteins of these viruses. In silico design and subsequent SAR study resulted in an identification of lead compounds 7 and 8 (Fig. 5 ) with ability to inhibit these critical viral-host (PPxY-Nedd4) interactions. 105 In addition, compounds 7 and 8 exhibited antibudding activity against EBOV and other RNA viruses and can thus serve as the lead structures for the development of novel broad-spectrum antivirals. PTAP type L domain is another domain utilized by number of RNA viruses (e.g., Junin virus, EBOV, HIV-1) during the budding process and, thus, recently identified PTAP inhibitors, such as compound 5593-0062 and its structural analogue 4816-0013 (Fig. 5) , have the potential to act as potent broad-spectrum, host-oriented antiviral drugs. RNA viruses present a good target for the rapidly advancing field of sequence-specific therapeutics. [107] [108] [109] [110] Antisense strategy usually utilize single-stranded DNA oligonucleotides to inhibit protein production by binding to specific sites on mRNA essential for translation, or by mediating the catalytic degradation of target mRNA, 111 while double-stranded RNA oligonucleotides, known as short-interfering RNAs (siRNAs), also mediate the catalytic degradation of complementary mRNAs. Thus, both antisense and RNAi strategies can find therapeutic applications for treatment of highly pathogenic RNA viral infections. Phosphorodiamidate morpholino oligomers (PMOs) were designed to inhibit translation of EBOV VP35, VP24, and L transcripts. 112, 113 All anti-EBOV PMOs reported showed reduced viral titer in cell cultures and provided complete protection to rodents when administered in both pre-and postexposure therapeutic regimens. PMOs also protected 75% of rhesus macaques in a prophylactic regimen. 113 Sarepta Therapeutics (Cambridge, MA, USA, formerly AVI BioPharma) has developed PMO containing up to five positively charged linkages (PMOplus, Fig. 6 ) 114, 115 that have significantly improved the stability, efficacy, specificity, delivery, and safety of antisense complexes. Chemical evolution of the antisense molecules led to the discovery of two new therapeutic agents, AVI-7537 targeting the VP24 transcript of EBOV and AVI-7288 targeting the NP transcript of MARV. 116 The VP24 protein is an inhibitor of type I interferon responses. It also forms homodimers and binds to VP35 or NP and, thus, may play an important role in the switch from viral replication to transcription, a function that is critical to the viral life cycle. Inhibition of VP24 may lead to an efficient host response to viral infection. Recently, Heald et al. 117 evaluated the safety and pharmacokinetic properties of two combination drugs AVI-6002 (a combination of AVI-7537 and AVI-7539) and AVI-6003 (a combination of AVI-7287 and AVI-7288) that are under evaluation for postexposure prophylaxis of EBOV and MARV, respectively. Additional studies in nonhuman primates and humans are in progress to estimate the protective human doses. 117 RNAi may also prove to be an effective and druggable therapy against filovirus infections. 118-120 siRNAs targeting EBOV RNA polymerase, formulated in stable nucleic acid lipid particles (SNALPs), 121 completely protected guinea pigs when administered shortly after an EBOV challenge. 118 The siRNA proof-of-concept experiment in non-human primates against a lethal Ebola virus infection showed 66% and full postexposure protection of rhesus monkeys and macaques, respectively. 122 Although the observation of adverse events (as fever) in some subjects in a Phase I study caused TKM-Ebola, siRNA developed by Tekmira Pharmaceuticals (Burnaby, Canada), to be placed on partial clinical hold, the FDA has still authorized its use in treating patients with confirmed or suspected EBOV infection under expanded access protocols. The development of successful antiviral therapies to treat filovirus diseases is under way. The research programs should be facilitated by use of specific technologies and strategies, 123, 124 as well as high-throughput systems 125, 126 and suitable animal models, 127-130 that have been recently reported. Especially, the use of laboratory animals is fundamental for the development of potent antifiloviral agents. Since guinea pigs are, for their size, less useful, newborn mice and immunodeficient adult mice represent a suitable model for preliminary testing of potential vaccines and antiviral agents. 16 But namely use of non-human primates (NHPs), in which filoviruses cause severe VHF, is crucial for the successful development of efficient anti-EBOV treatments. 16 All of the filoviral proteins (GP, L, NP, VP24, VP30, VP35, and VP40) 16, 131 can potentially be chosen as a suitable target for development of druggable anti-EBOV agents. For example, VP24 and VP35, and RNA-dependent RNA polymerase L have been shown so far to be exploitable targets for potential antiviral therapy. It has also been demonstrated that host-directed therapeutics, those targeting host proteins (e.g., TSG101, SAH hydrolase), represent another viable approach to combat various viral diseases. The number of small-molecule inhibitors was shown to interfere with the filoviral entry/fusion step, but mode of action of many other inhibitors of viral replications is not yet known or fully understood. Two potential small-molecule antivirals were intended to be tested in human trials during the 2014 epidemic in Africa: brincidofovir (as orally bioavailable prodrug of cidofovir), an experimental drug originally developed by Chimerix to treat DNA viruses, 55 and favipiravir from Toyama Chemicals, approved in Japan to treat influenza. 132 These agents were considered to receive the Fast Track designation from FDA to speed up the development of potent anti-EBOV drugs as much as possible. Although this most frightening disease is endemic mainly to developing and third-world African countries, the recent Ebola outbreak has triggered new drug-and vaccine-development programs by a number of pharmaceutical companies, as well as by many academic research teams. It has become evident that remaining challenge for development of any VHF treatment currently is to move the most promising vaccine and drug candidates forward into human trials, so we are ready when the next Ebola outbreak strikes. Virus nomenclature below the species level: A standardized nomenclature for natural variants of viruses assigned to the family Filoviridae Defense against filoviruses used as biological weapons Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations Report of a WHO/International Study Team Report of an International Commission World Health Organization. Ebola virus disease Fact sheet No Ebola virus disease outbreak in West Africa Case fatality rate for Ebola virus disease in west Africa Exotic emerging viral diseases: Progress and challenges Cutaneous manifestations of filovirus infections André-vonArnim A. Clinical presentation and management of severe Ebola virus disease Ebola haemorrhagic fever Ebola virus: Unraveling pathogenesis to combat a deadly disease Molecular strategies to inhibit the replication of RNA viruses Experimental therapy of filovirus infections A cutting-edge view on the current state of antiviral drug development Post-exposure therapy of filovirus infections Potential vaccines and post-exposure treatments for filovirus infections Development of therapeutics for treatment of Ebola virus infection Small molecule inhibitors of ebola virus infections Ebola virus (EBOV) infection: Therapeutic strategies Potential and emerging treatment options for Ebola virus disease Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp Filovirus vaccines Current Ebola vaccines Ebola virus vaccines: An overview of current approaches Mechanism of action of ribavirin against distinct viruses Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug Inhibition of Ebola virus replication in vitro and in a SCID mouse model by S-adenosylhomocysteine hydrolase inhibitors Antiviral drug therapy of filovirus infections: Sadenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor Carbocyclic analogue of 3-deazaadenosine: A novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents Carbocyclic adenosine analogues as S-adenosylhomocysteine hydrolase inhibitors and antiviral agents: Recent advances Montgomery's Legacy: Carbocyclic adenosine analogues as SAH hydrolase inhibitors with broad-spectrum antiviral activity 3-Deazaneplanocin A induces massively increased interferon-α production in Ebola virus-infected mice Antivirals and antiviral strategies The enantiomers of the 1',6'-isomer of neplanocin A: Synthesis and antiviral properties Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes Transition states, analogues, and drug development BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model Adenovirus: Current epidemiology and emerging approaches to prevention and treatment In vitro efficacy of Brincidofovir against Variola virus Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines Acyclic nucleoside phosphonates: A key class of antiviral drugs CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation Chimerix announces emergency investigational new drug applications for brincidofovir authorized by FDA for patients with Ebola virus disease Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections Favipiravir (T-705), a novel viral RNA polymerase inhibitor vitro and in vivo activities of anti-influenza virus compound T-705 Mechanism of action of T-705 against influenza virus Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model The ambiguous basepairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5 -triphosphate towards influenza A virus polymerase T-705 (Favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection A broad-spectrum antiviral targeting entry of enveloped viruses A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion Identification of a small-molecule entry inhibitor for filoviruses Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: Involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay Fullerene sugar balls: A new class of biologically active fullerene derivatives Glycofullerenes inhibit viral infection A systematic screen of FDA-approved drugs for inhibitors of biological threat agents Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection Chlorpromazine for schizophrenia: A Cochrane systematic review of 50 years of randomised controlled trials Ebola virus uses clathrin mediated endocytosis as an entry pathway FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit ebola virus entry and infection The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology Antiviral activity of a small-molecule inhibitor of filovirus infection Development of a broad-spectrum antiviral with activity against Ebola virus Targeting the host or the virus: Current and novel concepts for antiviral approaches against influenza virus infection A chemotype that inhibits three unrelated pathogenic targets: The botulinum neurotoxin serotype a light chain, p. Falciparum malaria, and the ebola filovirus A limited structural modification results in a significantly more efficacious diazachrysene-based filovirus inhibitor FGI-104: A broad-spectrum small molecule inhibitor of viral infection No exit: Targeting the budding process to inhibit filovirus replication Bimolecular complementation to visualize filovirus VP40-host complexes in live mammalian cells: Toward the identification of budding inhibitors Methods of inhibiting viral infection Broad-spectrum antiviral activity including human immunodeficiency and hepatitis C viruses mediated by a novel retinoid thiosemicarbazone derivative Retinazone inhibits certain bloodborne human viruses including Ebola virus Zaire Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo Competitive inhibitor of cellular alphaglucosidases protects mice from lethal dengue virus infection Small molecule inhibitors of ER alpha-glucosidases are active against multiple hemorrhagic fever viruses Structure of the Ebola VP35 interferon inhibitory domain Ebolavirus VP35 is a multifunctional virulence factor In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus Identification of an antioxidant small-molecule with broad-spectrum antiviral activity Small-molecule probes targeting the viral PPxY-host Nedd4 interface blco egress of a broad range of RNA viruses A hostoriented inhibitor of Junin Argentine hemorrhagic fever virus egress Antisense oligonucleotides: Basic concepts and mechanisms Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses Incorporation of positively charged linkages into DNA and RNA backbones: A novel strategy for antigene and antisense agents mRNA-based therapeitics-Developing a new class of drugs Antisense oligonucleotides: From design to therapeutic application Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice Advanced antisense therapies for postexposure protection against lethal filovirus infections Advanced morpholino oligomers: A novel approach to antiviral therapy Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against Ebola virus and Marburg virus: Results of two single-ascending-dose studies Inhibition of Marburg virus protein expression and viral release by RNA interference Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study Development of treatment strategies to combat Ebola and Marburg viruses Treatment of Marburg and Ebola hemorrhagic fevers: A strategy for testing new drugs and vaccines under outbreak conditions A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses Animal models of highly pathogenic RNA viral infections: Hemorrhagic fever viruses Mouse models for Filovirus infections Animal models for Ebola and Marburg virus infections Animal models for highly pathogenic emerging viruses Filoviridae: Marburg and ebola viruses